ATARA Biotherapeutics (ATRA) Misses Q3 EPS by 9c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79).

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30